Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | retinoid X receptor, gamma | Starlite/ChEMBL | References |
Homo sapiens | retinoic acid receptor, alpha | Starlite/ChEMBL | References |
Mus musculus | retinoid X receptor gamma | Starlite/ChEMBL | References |
Homo sapiens | retinoid X receptor, alpha | Starlite/ChEMBL | References |
Homo sapiens | retinoid X receptor, beta | Starlite/ChEMBL | References |
Mus musculus | retinoid X receptor beta | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | ecdysteroid receptor | retinoid X receptor gamma | 340 aa | 338 aa | 24.6 % |
Brugia malayi | ecdysteroid receptor | retinoid X receptor, alpha | 435 aa | 352 aa | 23.9 % |
Brugia malayi | ecdysteroid receptor | retinoid X receptor, gamma | 340 aa | 338 aa | 24.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.029 | 0.0583 | 1 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0824 | 1 | 0.5 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0787 | 0.9347 | 0.5 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0327 | 0.1236 | 0.5 |
Brugia malayi | nuclear hormone receptor | 0.029 | 0.0583 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 20 nM | Transcriptional activation in CV-1 cells expressing Retinoid X receptor alpha | ChEMBL. | 15006411 |
EC50 (binding) | = 20 nM | Transcriptional activation in CV-1 cells expressing Retinoid X receptor alpha | ChEMBL. | 15006411 |
Efficacy (functional) | = 21 % | In vitro agonist efficacy at human Retinoic X receptor alpha expressed in CV1 cells. | ChEMBL. | 15006411 |
Efficacy (functional) | = 21 % | In vitro agonist efficacy at human Retinoic X receptor alpha expressed in CV1 cells. | ChEMBL. | 15006411 |
Efficacy (functional) | = 26 % | In vitro agonist efficacy at human Retinoic X receptor alpha expressed in CV1 cells. | ChEMBL. | 15006411 |
Efficacy (functional) | = 26 % | In vitro agonist efficacy at human Retinoic X receptor alpha expressed in CV1 cells. | ChEMBL. | 15006411 |
IC50 (binding) | 0 nM | Transcriptional activation in CV-1 cells expressing Retinoic X receptor alpha; NC denotes as not calculated | ChEMBL. | 15006411 |
Ki (binding) | = 6 nM | Binding affinity against Retinoic acid receptor RXR-alpha by [3H]-9-cis-RA displacement. | ChEMBL. | 15006411 |
Ki (binding) | = 6 nM | Binding affinity against Retinoic acid receptor RXR-alpha by [3H]-9-cis-RA displacement. | ChEMBL. | 15006411 |
Ki (binding) | = 11 nM | Displacement of [3H]-9-cis-RA from Retinoic X receptor beta | ChEMBL. | 15006411 |
Ki (binding) | = 11 nM | Displacement of [3H]-9-cis-RA from Retinoic X receptor beta | ChEMBL. | 15006411 |
Ki (binding) | = 12 nM | Displacement of [3H]-9-cis-RA from retinoic X receptor gamma | ChEMBL. | 15006411 |
Ki (binding) | = 12 nM | Displacement of [3H]-9-cis-RA from retinoic X receptor gamma | ChEMBL. | 15006411 |
Ki (binding) | = 5940 nM | Binding affinity again retinoic acid receptor beta by [3H]-ATRA displacement. | ChEMBL. | 15006411 |
Ki (binding) | = 5940 nM | Binding affinity again retinoic acid receptor beta by [3H]-ATRA displacement. | ChEMBL. | 15006411 |
Ki (binding) | > 10000 nM | Binding affinity against retinoic acid receptor alpha by [3H]-ATRA displacement. | ChEMBL. | 15006411 |
Ki (binding) | = 10000 nM | Binding affinity against retinoic acid receptor gamma by [3H]-ATRA displacement. | ChEMBL. | 15006411 |
Ki (binding) | > 10000 nM | Binding affinity against retinoic acid receptor alpha by [3H]-ATRA displacement. | ChEMBL. | 15006411 |
Ki (binding) | = 10000 nM | Binding affinity against retinoic acid receptor gamma by [3H]-ATRA displacement. | ChEMBL. | 15006411 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.